Alterity Therapeutics (PRNAD) Research & Development (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Research & Development for 10 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Research & Development rose 42.4% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $15.6 million (up 1.7% YoY), while the FY2025 annual figure was $9.2 million, down 100.0% from the prior year.
• Research & Development came in at $4.3 million for Q4 2025 at Alterity Therapeutics, up from $3.0 million in the prior quarter.
• The five-year high for Research & Development was $4.3 million in Q4 2025, with the low at $3.0 million in Q4 2024.
• Average Research & Development over 5 years is $3.9 million, with a median of $4.1 million recorded in 2023.
• Across the five-year window, Research & Development fell 26.77% in 2024 and jumped 42.4% in 2025, its largest moves.
• Year by year, Research & Development stood at $4.1 million in 2021, then climbed by 2.3% to $4.2 million in 2022, then retreated by 0.23% to $4.1 million in 2023, then dropped by 26.77% to $3.0 million in 2024, then surged by 42.4% to $4.3 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $4.3 million, $3.0 million, and $4.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.